Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 409823, 9 pages
http://dx.doi.org/10.1155/2012/409823
Research Article

Aqueous Extract of Paeonia suffruticosa Inhibits Migration and Metastasis of Renal Cell Carcinoma Cells via Suppressing VEGFR-3 Pathway

1Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan
2School of Pharmacy, College of Medicine, National Taiwan University, Taipei 10051, Taiwan
3Department of Pathology, National Taiwan University Hospital, Taipei 10002, Taiwan
4Graduate Institute of Integrated Medicine of Chinese Medicine, China Medical University, Taichung, Taiwan
5Department of Medical Genetics and Medical Research, China Medical University Hospital, Taichung, Taiwan

Received 28 June 2011; Accepted 2 November 2011

Academic Editor: Lixing Lao

Copyright © 2012 Shih-Chin Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Markman, “Safety issues in using complementary and alternative medicine,” Journal of Clinical Oncology, vol. 20, no. 18, pp. 39S–41S, 2002. View at Google Scholar · View at Scopus
  2. Y. Cui, X. O. Shu, Y. Gao et al., “Use of complementary and alternative medicine by Chinese women with breast cancer,” Breast Cancer Research and Treatment, vol. 85, no. 3, pp. 263–270, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. M. A. Richardson, T. Sanders, J. L. Palmer, A. Greisinger, and S. E. Singletary, “Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology,” Journal of Clinical Oncology, vol. 18, no. 13, pp. 2505–2514, 2000. View at Google Scholar · View at Scopus
  4. H. C. Lin, H. Y. Ding, and Y. C. Wu, “Two novel compounds from Paeonia suffruticosa,” Journal of Natural Products, vol. 61, no. 3, pp. 343–346, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. C. L. Hsieh, C. Y. Cheng, T. H. Tsai et al., “Paeonol reduced cerebral infarction involving the superoxide anion and microglia activation in ischemia-reperfusion injured rats,” Journal of Ethnopharmacology, vol. 106, no. 2, pp. 208–215, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Li, W. Zhang, L. Huang, and J. Shi, “Pharmacological of cortex moutan and core,” Zhongguo Zhong Yao Za Zhi, vol. 22, no. 4, pp. 214–254, 1997. View at Google Scholar · View at Scopus
  7. G. S. Oh, H. O. Pae, H. Oh et al., “In vitro anti-proliferative effect of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose on human hepatocellular carcinoma cell line, SK-HEP-1 cells,” Cancer Letters, vol. 174, no. 1, pp. 17–24, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M. P. Sheehan and D. J. Atherton, “One-year follow up of children treated with Chinese medicinal herbs for atopic eczema,” British Journal of Dermatology, vol. 130, no. 4, pp. 488–493, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Okubo, F. Nagai, T. Seto, K. Satoh, K. Ushiyama, and I. Kano, “The inhibition of phenylhydroquinone-induced oxidative DNA cleavage by constituents of Moutan Cortex and Paeoniae Radix,” Biological and Pharmaceutical Bulletin, vol. 23, no. 2, pp. 199–203, 2000. View at Google Scholar · View at Scopus
  10. C. H. Lau, C. M. Chan, Y. W. Chan et al., “Pharmacological investigations of the anti-diabetic effect of Cortex Moutan and its active component paeonol,” Phytomedicine, vol. 14, no. 11, pp. 778–784, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. G. P. Sun, X. Wan, S. P. Xu, H. Wang, S. H. Liu, and Z. G. Wang, “Antiproliferation and apoptosis induction of paeonol in human esophageal cancer cell lines,” Diseases of the Esophagus, vol. 21, no. 8, pp. 723–729, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Sun, Y. Dong, H. J. Jiang et al., “Dissection of the role of paeoniflorin in the traditional Chinese medicinal formula Si-Ni-San against contact dermatitis in mice,” Life Sciences, vol. 84, no. 11-12, pp. 337–344, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S. P. Xu, G. P. Sun, Y. X. Shen, W. Wei, W. R. Peng, and H. Wang, “Antiproliferation and apoptosis induction of paenol in HepG2 cells,” World Journal of Gastroenterology, vol. 13, no. 2, pp. 250–256, 2007. View at Google Scholar · View at Scopus
  14. J. Y. Hung, C. J. Yang, Y. M. Tsai, H. W. Huang, and M. S. Huang, “Antiproliferative activity of paeoniflorin is through cell cycle arrest and the Fas/Fas ligand-mediated apoptotic pathway in human non-small cell lung cancer A549 cells,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 2, pp. 141–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Pantuck, A. Zisman, and A. Belldegrun, “The changing natural history of renal cell carcinoma,” Journal of Urology, vol. 166, pp. 1611–1623, 2001. View at Google Scholar · View at Scopus
  16. P. Russo, “Renal cell carcinoma: presentation, staging, and surgical treatment,” Seminars in Oncology, vol. 27, no. 2, pp. 160–176, 2000. View at Google Scholar · View at Scopus
  17. C. P. Pavlovich and L. S. Schmidt, “Searching for the hereditary causes of renal-cell carcinoma,” Nature Reviews Cancer, vol. 4, no. 5, pp. 381–393, 2004. View at Google Scholar · View at Scopus
  18. J. C. Cheville, C. M. Lohse, H. Zincke, A. L. Weaver, and M. L. Blute, “Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma,” American Journal of Surgical Pathology, vol. 27, no. 5, pp. 612–624, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. Amato, “Chemotherapy for renal cell carcinoma,” Seminars in Oncology, vol. 27, no. 2, pp. 177–186, 2000. View at Google Scholar · View at Scopus
  20. B. R. Lane, B. I. Rini, A. C. Novick, and S. C. Campbell, “Targeted molecular therapy for renal cell carcinoma,” Urology, vol. 69, no. 1, pp. 3–10, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. D. J. Van Spronsen, K. J. M. De Weijer, P. F. A. Mulders, and P. H. M. De Mulder, “Novel treatment strategies in clear-cell metastatic renal cell carcinoma,” Anti-Cancer Drugs, vol. 16, no. 7, pp. 709–717, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Ishimura, I. Sakai, I. Hara, H. Eto, and H. Miyake, “Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery,” International Journal of Urology, vol. 11, no. 5, pp. 264–268, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. S. Ernstoff, T. S. Crocenzi, J. D. Seigne et al., “Developing a rational tumor vaccine therapy for renal cell carcinoma: immune Yin and Yang,” Clinical Cancer Research, vol. 13, no. 2, pp. 733ss–740s, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. J. A. Glaspy, “Therapeutic options in the management of renal cell carcinoma,” Seminars in Oncology, vol. 29, no. 3, pp. 41–46, 2002. View at Google Scholar · View at Scopus
  25. E. Corey, L. G. Brown, J. E. Quinn et al., “Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer,” Clinical Cancer Research, vol. 9, no. 1, pp. 295–306, 2003. View at Google Scholar · View at Scopus
  26. G. Chen, P. Raman, P. Bhonagiri, A. B. Strawbridge, G. R. Pattar, and J. S. Elmendorf, “Protective effect of phosphatidylinositol 4,5-bisphosphate against cortical filamentous actin loss and insulin resistance induced by sustained exposure of 3T3-L1 adipocytes to insulin,” Journal of Biological Chemistry, vol. 279, no. 38, pp. 39705–39709, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. J. Cross, J. Dixelius, T. Matsumoto, and L. Claesson-Welsh, “VEGF-receptor signal transduction,” Trends in Biochemical Sciences, vol. 28, no. 9, pp. 488–494, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. C. A. Garces, E. V. Kurenova, V. M. Golubovskaya, and W. G. Cance, “Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells,” Cancer Research, vol. 66, no. 3, pp. 1446–1454, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. D. P. Choma, V. Milano, K. M. Pumiglia, and C. M. DiPersio, “Integrin α3β1-dependent activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5,” Journal of Investigative Dermatology, vol. 127, no. 1, pp. 31–40, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. S. J. Heasman and A. J. Ridley, “Mammalian Rho GTPases: new insights into their functions from in vivo studies,” Nature Reviews Molecular Cell Biology, vol. 9, no. 9, pp. 690–701, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Vignjevic and G. Montagnac, “Reorganisation of the dendritic actin network during cancer cell migration and invasion,” Seminars in Cancer Biology, vol. 18, no. 1, pp. 12–22, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Y. Cha, E. O. Lee, H. J. Lee et al., “Methylene chloride fraction of Scutellaria barbata induces apoptosis in human U937 leukemia cells via the mitochondrial signaling pathway,” Clinica Chimica Acta, vol. 348, no. 1-2, pp. 41–48, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. Q. Chen, W. Peng, S. Qi, and A. Xu, “Apoptosis of human highly metastatic lung cancer cell line 95-D induced by acutiaporberine, a novel bisalkaloid derived from Thalictrum acutifolium,” Planta Medica, vol. 68, no. 6, pp. 550–553, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. T. C. Hsieh, X. Lu, J. Guo et al., “Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies,” International Journal of Oncology, vol. 20, no. 4, pp. 681–689, 2002. View at Google Scholar · View at Scopus
  35. S. Y. Lin, J. D. Liu, H. C. Chang, S. D. Yeh, C. H. Lin, and W. S. Lee, “Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis,” Journal of Cellular Biochemistry, vol. 84, no. 3, pp. 532–544, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Ma, N. Y. Fu, D. B. Pang, W. Y. Wu, and A. L. Xu, “Apoptosis induced by isoliquiritigenin in human gastric cancer MGC-803 cells,” Planta Medica, vol. 67, no. 8, pp. 754–757, 2001. View at Google Scholar · View at Scopus
  37. X. A. Wan, G. P. Sun, H. Wang, S. P. Xu, Z. G. Wang, and S. H. Liu, “Synergistic effect of paeonol and cisplatin on oesophageal cancer cell lines,” Digestive and Liver Disease, vol. 40, no. 7, pp. 531–539, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. J. L. Su, C. J. Yen, P. S. Chen et al., “The role of the VEGF-C/VEGFR-3 axis in cancer progression,” British Journal of Cancer, vol. 96, no. 4, pp. 541–545, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Wang, M. Nakayama, M. E. Pitulescu et al., “Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis,” Nature, vol. 465, no. 7297, pp. 483–486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Bando, M. Brokelmann, M. Toi et al., “Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues,” International Journal of Cancer, vol. 111, no. 2, pp. 184–191, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Lian, J. Liu, M. Wu et al., “Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis,” Hepatology, vol. 45, no. 6, pp. 1390–1399, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. D. K. Dhar, H. Naora, A. Yamanoi et al., “Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway,” Anticancer Research, vol. 22, no. 1 A, pp. 379–386, 2002. View at Google Scholar · View at Scopus
  43. A. Salameh, F. Galvagni, M. Bardelli, F. Bussolino, and S. Oliviero, “Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways,” Blood, vol. 106, no. 10, pp. 3423–3431, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Besson, R. K. Assoian, and J. M. Roberts, “Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?” Nature Reviews Cancer, vol. 4, no. 12, pp. 948–955, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. A. J. Ridley, M. A. Schwartz, K. Burridge et al., “Cell migration: integrating signals from front to back,” Science, vol. 302, no. 5651, pp. 1704–1709, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Hall, “Rho GTpases and the actin cytoskeleton,” Science, vol. 279, no. 5350, pp. 509–514, 1998. View at Publisher · View at Google Scholar · View at Scopus